South Korean company LegoChem Biosciences (Kosdaq: 141080) and Germany’s Glycotope have signed a research collaboration and license agreement to develop an antibody drug conjugate (ADC).
The collaboration will see the companies combine LegoChem's proprietary ADC technology with one of Glycotope's investigational tumor targeting antibodies.
"ADCs with potential to perform beyond today’s best standard of care"Under the terms of the agreement, LegoChem has the right to exercise its option for worldwide exclusive rights to develop and commercialize the selected antibody as an ADC, upon successful completion of a feasibility study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze